Leerink Partners Believes AbbVie (NYSE: ABBV) Won’t Stop Here

Leerink Partners analyst Geoff Porges maintained a Buy rating on AbbVie (ABBVResearch Report) on June 28. The company’s shares closed last Wednesday at $112.64, close to its 52-week high of $118.28.

According to TipRanks.com, Porges is a 3-star analyst with an average return of 4.6% and a 48.0% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbbVie with a $122.82 average price target, a 9.5% upside from current levels. In a report issued on June 14, Evercore ISI also maintained a Buy rating on the stock with a $130.00 price target.

See today’s analyst top recommended stocks >>

AbbVie’s market cap is currently $198.9B and has a P/E ratio of 40.50. The company has a Price to Book ratio of -1.98.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.